Characteristics of the immune microenvironment of endometrial cancer depending on the MMR status of the tumor

Kalinchuk A.Yu.; Maltseva A.A.; Tsarenkova E.A.; Loos D.M.; Vtorushin S.V.; Kolomiets L.A.; Tashireva L.A.

doi:https://doi.org/10.17116/patol20258705111

Kalinchuk A.Yu.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0003-2106-3513

Maltseva A.A.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0001-8212-731X

Tsarenkova E.A.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0009-0009-7955-1625

Loos D.M.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0002-4098-6076

Vtorushin S.V.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0002-1195-4008

Kolomiets L.A.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0002-6854-8940

Tashireva L.A.

Cancer Research Institute — Tomsk National Research Medical Center of the Russian Academy of Sciences

ORCID: 0000-0003-2061-8417

Characteristics of the immune microenvironment of endometrial cancer depending on the MMR status of the tumor

Authors:

Kalinchuk A.Yu., Maltseva A.A., Tsarenkova E.A., Loos D.M., Vtorushin S.V., Kolomiets L.A., Tashireva L.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2025;87(5): 11‑19

DOI: 10.17116/patol20258705111

Read: 441 times

Contact the author

Table of contents

To cite this article:

Kalinchuk AYu, Maltseva AA, Tsarenkova EA, Loos DM, Vtorushin SV, Kolomiets LA, Tashireva LA. Characteristics of the immune microenvironment of endometrial cancer depending on the MMR status of the tumor. Russian Journal of Archive of Pathology. 2025;87(5):11‑19. (In Russ.)
https://doi.org/10.17116/patol20258705111

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

OBJECTIVE

To study the microenvironment features of MMR-proficient (pMMR) and MMR-deficient (dMMR) endometrial cancer.

MATERIAL AND METHODS

The study included 34 patients with pMMR endometrial cancer and 10 patients with dMMR endometrial cancer. Using the method of multiplex TSA-associated (tyramide signal amplification) immunofluorescence, phenotyping of the tumor microenvironment was performed with an assessment of stromal and intratumor cell localization and PD-1 expression.

RESULTS

In pMMR endometrial tumors, the predominant cell population was CD163+ macrophages, and in tumors with dMMR, CD163+ macrophages were found equally with CD8+ T lymphocytes and CD20+ B lymphocytes. In dMMR tumors, the number of CD8+ T lymphocytes and CD20+ B lymphocytes (as well as CD20+ B lymphocytes expressing PD-1) is higher compared to pMMR tumors, while the number of FoxP3+ T lymphocytes was significantly lower. The number of CD163+ macrophages did not differ depending on the MMR status, while the number of CD163+ macrophages was higher in the stroma compared to the number of these cells located intraepithelially. In patients with dMMR tumors, the number of CD8+ T lymphocytes was higher in the stroma, and did not differ in pMMR tumors.

CONCLUSION

In this study, it was found that dMMR endometrial tumors are characterized by an increase in the proportion of CD8+ T lymphocytes and CD20+ B lymphocytes, which may be associated with a better response to immunotherapy. The differences in spatial distribution of CD8+ T lymphocytes and CD163+ macrophages confirmed the importance of immune cell localization for prognosis and treatment efficacy. These results highlight the need for further study of the endometrial cancer microenvironment in order to personalize therapy.

Keywords:

endometrial cancer

microsatellite instability

tumor microenvironment

lymphocytes

macrophages

Authors:

Kalinchuk A.Yu.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0003-2106-3513

Maltseva A.A.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0001-8212-731X

Tsarenkova E.A.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0009-0009-7955-1625

Loos D.M.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0002-4098-6076

Vtorushin S.V.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0002-1195-4008

Kolomiets L.A.

Cancer Research Institute — Tomsk National Research Medical Center

ORCID: 0000-0002-6854-8940

Tashireva L.A.

Cancer Research Institute — Tomsk National Research Medical Center of the Russian Academy of Sciences

ORCID: 0000-0003-2061-8417

Received:

21.01.2025

Accepted:

25.06.2025

Close metadata

References:

Vanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z., Marshall, J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer medicine. 2018; 7(3): 746-756. https://doi.org/10.1002/cam4.1372
Fan C-T, Hsu S-T, Sun L, Hwang S-F, Liu C-K, Shih Y-H, Chen M-J, Li H-N, Wang J-S, Wen M-C, et al. Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer. Journal of Clinical Medicine. 2023;12(2):603. https://doi.org/10.3390/jcm12020603
Kono-Sato T, Miyai K, Yamagishi Y, Miyamoto M, Takano M, Matsukuma S, Sato K, Tsuda H. Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages. BMC Cancer. 2022;22:361. https://doi.org/10.1186/s12885-022-09363-0
Horeweg N, de Bruyn M, Nout RA, Stelloo E, Kedziersza K, León-Castillo A, Plat A, Mertz KD, Osse M, Jürgenliemk-Schulz IM et al. Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer. Cancer Immunology Research. 2020;8(12):1508-1519. https://doi.org/10.1158/2326-6066.CIR-20-0149
Munakata S, Ito T, Asano T, Yamashita T. Tumor-Infiltrating CD8-Positive T-Cells Associated with MMR and p53 Protein Expression Can Stratify Endometrial Carcinoma for Prognosis. Diagnostics. 2023;13(12):1985. https://doi.org/10.3390/diagnostics13121985
Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, Tsuda H, Tsukazaki K, Aoki D. Immunofluorescence-Detected Infiltration of CD4+FOXP3+ Regulatory T Cells Is Relevant to the Prognosis of Patients With Endometrial Cancer. International Journal of Gynecological Cancer. 2011;21(9):1628-1634. https://doi.org/10.1097/IGC.0b013e31822c271f
Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH, Yates MS. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clinical cancer research. 2017;23(15):4473-4481. https://doi.org/10.1158/1078-0432.CCR-16-2655
Dai Y, Zhao L, Hua D, Cui L, Zhang X, Kang N, Qu L, Li L, Li H, Shen D et al. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study. Frontiers in Immunology. 2022;13:1035616. https://doi.org/10.3389/fimmu.2022.1035616
Maiorano BA, Maiorano MFP, Cormio G, Maglione A, Lorusso D, Maiello E. How immunotherapy modified the therapeutic scenario of endometrial cancer: A systematic review. Frontiers in Oncology. 2022;12:844801. https://doi.org/10.3389/fonc.2022.844801
Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site — when a biomarker defines the indication. New England Journal of Medicine. 2017;377(15):1409-1412. https://doi.org/10.1056/NEJMp1709968
Cao W, Ma X, Fischer JV, Sun C, Kong B, Zhang Q. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomarker Research. 2021;9:49. https://doi.org/10.1186/s40364-021-00301-z
Mamat Yusof MN, Chew KT, Kampan NC, Shafiee MN. Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance. International journal of molecular sciences. 2023;24(20):15233. https://doi.org/10.3390/ijms242015233
Deng J, Jiang W, Liu L, Zhan W, Wu Y, Xu X. Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review). Oncology Letters. 2022;25(1):10. https://doi.org/10.3892/ol.2022.13596
Tashireva LA, Perelmuter VM, Manskikh VN, Denisov EV, Savelieva OE, Kaygorodova EV, Zavyalova MV. Types of Immune-Inflammatory Responses as a Reflection of Cell-Cell Interactions under Conditions of Tissue Regeneration and Tumor Growth. Biochemistry (Mosc). 2017;82(5):542-555. https://doi.org/10.1134/S0006297917050029
Grau Bejar JF, Yaniz Galende E, Zeng Q, Genestie C, Rouleau E, de Bruyn M, Klein C, Le Formal A, Edmond E, Moreau M et al. Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. Journal for ImmunoTherapy of Cancer. 2024;12(7):e009143. https://doi.org/10.1136/jitc-2024-009143
Maltseva A, Kalinchuk A, Chernorubashkina N, Sisakyan V, Lots I, Gofman A, Anzhiganova Y, Martynova E, Zukov R, Aleksandrova E et al. Predicting Response to Immunotargeted Therapy in Endometrial Cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study. International Journal of Molecular Sciences. 2024;25(7):3933. https://doi.org/10.3390/ijms25073933
Li J, Wu C, Hu H, Qin G, Wu X, Bai F, Zhang J, Cai Y, Huang Y, Wang C et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023;41(6):1152-1169.e7. https://doi.org/10.1016/j.ccell.2023.04.011